Multiple Myeloma Hub Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Jan 14, 2022
Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.
Chapters
Transcript
Episode notes
1 2 3 4
Introduction
00:00 • 3min
Impact of DARATUMUMAB in Maintenance Therapy for Newly Diagnosed Multiple Myeloma Patients
03:07 • 3min
Treatment Efficacy Comparison in Newly Diagnosed Multiple Myeloma Patients
06:37 • 3min
The Impact of Daratumumab Maintenance Therapy on Progression-Free Survival in Multiple Myeloma Patients
09:32 • 4min